Pharmaceutical Benefits Scheme limitations on macrolides: implications for pertussis management.

Jarvinen Kari A J, McCall Bradley J, Nourse Clare B, McCormack Joe G, Tilse Martyn H

Med J Aust. 2006 Mar 20;184(6):309. doi: 10.5694/j.1326-5377.2006.tb00251.x.

Abstract

摘要

相似文献

Med J Aust. 2006 Mar 20;184(6):309. doi: 10.5694/j.1326-5377.2006.tb00251.x.

Arch Dis Child. 2005 Mar;90(3):322-4. doi: 10.1136/adc.2004.068783.

Pediatr Infect Dis J. 2021 Feb 1;40(2):87-90. doi: 10.1097/INF.0000000000002911.

Med J Aust. 2009 Apr 6;190(7):388-9. doi: 10.5694/j.1326-5377.2009.tb02455.x.

Pediatr Infect Dis J. 2006 Jan;25(1):96; author reply 96. doi: 10.1097/01.inf.0000195753.50341.56.

J Glob Antimicrob Resist. 2019 Sep;18:47-51. doi: 10.1016/j.jgar.2019.01.029. Epub 2019 Jan 30.

Med J Aust. 2003 Feb 17;178(4):191; author reply 191. doi: 10.5694/j.1326-5377.2003.tb05150.x.

J Pediatric Infect Dis Soc. 2018 Aug 17;7(3):e123-e125. doi: 10.1093/jpids/pix044.

Arch Pediatr Adolesc Med. 2002 Oct;156(10):1057-8.

Cochrane Database Syst Rev. 2005 Jan 25(1):CD004404. doi: 10.1002/14651858.CD004404.pub2.

Pharmacol Res Perspect. 2023 Jun;11(3):e01106. doi: 10.1002/prp2.1106.

20分钟写一篇综述，助力文献阅读效率提升50倍。

大模型驱动的PubMed中文搜索引擎

学术文献翻译模型，支持多种主流文档格式。